首頁 > 市場調查報告書 > 製藥

麻醉

市場調查報告書

商品編碼

1961109

麻醉劑市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、給藥途徑、地區和競爭格局分類，2021-2031年

Anesthesia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Route of Administration, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球麻醉劑市場預計將從 2025 年的 39.2 億美元成長到 2031 年的 62.4 億美元，複合年成長率為 8.06%。

這些藥物對於誘導可逆性感覺和意識喪失至關重要，從而確保診斷和手術操作的安全進行。市場成長趨勢主要受全球手術量增加的推動，而手術量的增加又源自於人口老化和需要手術治療的慢性疾病病例的增加。此外，新興市場門診手術中心的普及和醫療基礎設施的完善也為持續的需求奠定了堅實的基礎，凸顯了麻醉藥物治療在現代醫學中的關鍵作用。

市場概覽
預測期	2027-2031
市場規模：2025年	39.2億美元
市場規模：2031年	62.4億美元
複合年成長率：2026-2031年	8.06%
成長最快的細分市場	全身麻醉劑
最大的市場	北美洲

儘管市場具有成長潛力，但供應鏈脆弱性和生產不規範等問題仍構成重大障礙。其中一個主要障礙是頻繁發生的急性藥物短缺，這會擾亂臨床工作流程並使治療安排變得複雜。根據美國醫療保健系統藥劑師協會 (ASHP) 的數據，2024 年第一季有效藥物短缺事件達到創紀錄的 323 起，嚴重影響了無菌注射和基本麻醉劑的供應。這種不穩定性迫使醫療機構推遲治療或依賴替代方案，造成市場波動，限制了整體市場的擴張能力。

市場促進因素

推動全球麻醉劑市場成長的主要因素是全球外科手術數量的增加，這既包括創傷性急性病例，也包括擇期手術。隨著醫療系統從過去的混亂中恢復，麻醉劑數量顯著增加，直接帶動了全身麻醉、區域麻醉和局部麻醉劑的消耗。這一趨勢在積極開展擇期手術以改善患者照護的麻醉劑公共醫療機構中尤為明顯。例如，根據英國國家醫療服務體系（NHS England）2025年7月發布的《月度手術統計數據》，僅2025年5月，醫療機構開展的擇期手術數量就達到了創紀錄的150萬例，表明手術活動顯著增加，因此需要穩定的麻醉劑供應。

同時，人口老化的快速成長是推動麻醉劑市場發展的根本動力，因為老年人更容易因老齡化相關疾病而需要手術。這種人口結構的變化持續推高了對麻醉劑的需求，尤其是那些適用於合併多種疾病且對鎮靜劑更為敏感的患者。根據世界衛生組織（世衛組織）於2025年2月發布的最新全球老化數據，2024年出生時的平均壽命將達到73.3歲，凸顯了需要醫療干預的老年人群體不斷擴大。這為製造商創造了穩定的收入來源。例如，Hikma Pharmaceuticals在其於2025年2月發布的「2024會計年度財務業績報告」中指出，其主要麻醉劑供應業務——注射麻醉劑業務的收入在2024年成長了9%，達到13億美元。

市場挑戰

供應鏈脆弱性和生產不穩定是全球麻醉劑市場成長的主要障礙。這些運作問題經常導致神經肌肉阻斷劑和鎮痛藥等外科手術必需的無菌注射藥物供不應求。一旦因品管問題或原料短缺導致生產中斷，醫療機構將面臨庫存短缺的困境。這種不穩定性會降低麻醉劑藥品的整體消耗量，迫使醫院推遲擇期手術並減少手術室排班，直接阻礙市場成長。

這些供應中斷造成的經濟影響巨大，供應不穩定削弱了醫療服務提供者的信心，並威脅其收入的永續性。近期行業數據顯示，這一問題持續存在。根據美國系統藥劑師協會 (ASHP) 的報告，2024 年約 46% 的新藥短缺與注射劑（麻醉劑的主要給藥途徑）有關。基本製劑頻繁短缺會擾亂臨床計劃，迫使使用效果欠佳的替代品，並最終限制該行業的盈利能力和穩定性。

市場趨勢

隨著全球醫療系統努力實現臨床營運的脫碳，採用永續且環保的麻醉技術正在改變這一領域。醫療機構正在加速從高全球暖化潛勢值（GWP）的揮發性氣體（如地氟烷）轉向低碳替代方案，例如SEVOFLURANE和全靜脈麻醉（TIVA）。這項轉變旨在透過最大限度地減少空氣污染和提高氣體供應效率來降低對環境的影響。這種轉變的經濟效益也日益顯現。英國國家醫療服務體系（NHS）於2025年2月發布的《綠色規劃指南》指出，設定減少醫用氣體管道中氧化亞氮廢棄物的目標，每年將節省約500萬英鎊。這表明，環保策略不僅具有環境價值，而且具有經濟可行性。

同時，多方面鎮痛和減少鴉片類藥物用量的鎮痛方法的廣泛應用，刺激了對創新非麻醉性疼痛管理解決方案的需求。為了應對鴉片類藥物危機並改善手術效果，醫療機構正在將局部麻醉劑和神經阻斷納入加速復健外科（ERAS）通訊協定。這項策略減少了對全身性鴉片類藥物的依賴，從而減少了術後併發症並促進了患者更早出院。這種需求的激增正在對市場消費模式產生重大影響。在2025會計年度第一季財報（2025年5月）中，Pasila Biosciences公司報告稱，其非鴉片類止痛藥Exparel在2025年第一季的淨銷售額達到1.365億美元。這主要得益於平均每日用量增加了7%。

The Global Anesthesia Drugs Market is projected to expand from a valuation of USD 3.92 billion in 2025 to USD 6.24 billion by 2031, reflecting a compound annual growth rate of 8.06%. These pharmacological agents are essential for inducing reversible loss of sensation or consciousness, enabling safe diagnostic and surgical interventions. The market's upward trajectory is largely underpinned by the rising volume of global surgeries, driven by an aging demographic and a higher prevalence of chronic diseases necessitating operative care. Additionally, the proliferation of ambulatory surgical centers and the development of healthcare infrastructure in emerging markets provide a solid foundation for continued demand, highlighting the critical role of anesthetic pharmacotherapy in contemporary medicine.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.92 Billion
Market Size 2031	USD 6.24 Billion
CAGR 2026-2031	8.06%
Fastest Growing Segment	General Anesthesia Drugs
Largest Market	North America

Despite this growth potential, the market faces substantial obstacles stemming from supply chain fragility and manufacturing irregularities. A major impediment is the frequent occurrence of acute medication shortages, which interrupts clinical workflows and complicates scheduling. Data from the American Society of Health-System Pharmacists indicates that in the first quarter of 2024, active drug shortages reached a record high of 323, severely affecting the availability of sterile injectables and vital anesthesia drugs. Such instability compels healthcare providers to postpone procedures or resort to alternatives, creating volatility that restricts the market's overall capacity for expansion.

Market Driver

The primary force accelerating the Global Anesthesia Drugs Market is the escalating number of surgical procedures worldwide, driven by both acute trauma cases and planned interventions. As health systems recover from past disruptions, there has been a notable surge in surgical throughput, which directly fuels the consumption of general, regional, and local anesthetics. This trend is especially pronounced in major public health sectors where backlogs of elective cases are being aggressively managed to enhance patient care. For example, NHS England's 'Monthly operational statistics' from July 2025 reveal that healthcare providers completed a record 1.5 million elective treatments in May 2025 alone, indicating a significant intensification of surgical activity that requires a reliable supply of anesthetics.

In parallel, the rapid growth of the geriatric population acts as a fundamental driver, given that older adults disproportionately require surgery for age-related ailments. This demographic shift sustains demand for anesthetic agents specifically suited for patients with complex comorbidities and heightened sensitivity to sedation. According to the World Health Organization's February 2025 update on global ageing, life expectancy at birth rose to 73.3 years in 2024, highlighting the expanding cohort of elderly individuals needing medical intervention. This creates a consistent revenue stream for manufacturers; notably, Hikma Pharmaceuticals reported in their 'Annual Results 2024' (February 2025) that their Injectables business, a key anesthesia supplier, achieved a 9% revenue increase to $1.3 billion in 2024.

Market Challenge

Supply chain vulnerabilities and inconsistencies in manufacturing represent a significant hurdle to the growth of the Global Anesthesia Drugs Market. These operational failures often lead to shortages of critical sterile injectables, such as neuromuscular blockers and analgesics, which are essential for surgical procedures. When production is halted due to quality control issues or raw material shortages, healthcare facilities face immediate gaps in inventory. This instability directly inhibits market growth by forcing hospitals to delay elective surgeries or curtail operating room schedules, thereby reducing the overall volume of anesthetic product consumption.

The economic repercussions of these disruptions are substantial, as unreliability undermines provider confidence and threatens revenue continuity. The persistence of this problem is highlighted by recent industry data; the American Society of Health-System Pharmacists reported that in 2024, approximately 46% of new drug shortages involved injectable medications, the primary form of anesthesia delivery. This high frequency of deficits in essential formulations disrupts clinical planning and necessitates the use of less ideal alternatives, ultimately limiting the sector's revenue potential and stability.

Market Trends

The adoption of sustainable and green anesthesia practices is transforming the sector as healthcare systems around the world seek to decarbonize clinical operations. Institutions are increasingly moving away from volatile gases with high global warming potential, such as desflurane, in favor of lower-carbon alternatives like sevoflurane or Total Intravenous Anesthesia (TIVA). This shift aims to minimize atmospheric pollution and improve gas delivery efficiency to lessen environmental impact. The financial benefits of this transition are becoming evident; NHS England's 'Green plan guidance' from February 2025 notes that targeting nitrous oxide waste reduction in medical gas pipelines is generating annual savings of approximately £5 million, demonstrating the economic viability of eco-friendly strategies alongside their environmental value.

Concurrently, the increasing use of multimodal and opioid-sparing analgesia is stimulating demand for innovative non-narcotic pain management solutions. To address the opioid crisis and enhance surgical outcomes, providers are incorporating long-acting local anesthetics and nerve blocks into Enhanced Recovery After Surgery (ERAS) protocols. This strategy lessens dependence on systemic opioids, thereby reducing postoperative complications and speeding up patient discharge. This surge in demand is significantly affecting market consumption patterns; Pacira BioSciences reported in their 'First Quarter 2025 Financial Results' (May 2025) that net product sales for their non-opioid analgesic EXPAREL reached $136.5 million in Q1 2025, driven by a 7% increase in average daily volume usage.

Key Market Players

Pfizer Inc.
Merck & Co., Inc.
GSK Plc
Bayer AG
Dr. Reddy's Laboratories Ltd.
Viatris Inc.
AstraZeneca Plc
Abbott Laboratories Inc.
Sun Pharmaceutical Industries Ltd.
Eli Lilly and Company

Report Scope

In this report, the Global Anesthesia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anesthesia Drugs Market, By Type

General Anesthesia Drugs
Local Anesthesia Drugs

Anesthesia Drugs Market, By Application

General Surgery
Plastic Surgery
Cosmetic Surgery
Dental Surgery
Others

Anesthesia Drugs Market, By Route of Administration

Inhalation
Intravenous
Others

Anesthesia Drugs Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anesthesia Drugs Market.

Available Customizations:

Global Anesthesia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anesthesia Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (General Anesthesia Drugs, Local Anesthesia Drugs)
- 5.2.2. By Application (General Surgery, Plastic Surgery, Cosmetic Surgery, Dental Surgery, Others)
- 5.2.3. By Route of Administration (Inhalation, Intravenous, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Anesthesia Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Route of Administration
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anesthesia Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By Route of Administration
- 6.3.2. Canada Anesthesia Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By Route of Administration
- 6.3.3. Mexico Anesthesia Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By Route of Administration

7. Europe Anesthesia Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Route of Administration
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anesthesia Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By Route of Administration
- 7.3.2. France Anesthesia Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By Route of Administration
- 7.3.3. United Kingdom Anesthesia Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By Route of Administration
- 7.3.4. Italy Anesthesia Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By Route of Administration
- 7.3.5. Spain Anesthesia Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By Route of Administration

8. Asia Pacific Anesthesia Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Route of Administration
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Anesthesia Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By Route of Administration
- 8.3.2. India Anesthesia Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By Route of Administration
- 8.3.3. Japan Anesthesia Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By Route of Administration
- 8.3.4. South Korea Anesthesia Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By Route of Administration
- 8.3.5. Australia Anesthesia Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Anesthesia Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Route of Administration
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Anesthesia Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By Route of Administration
- 9.3.2. UAE Anesthesia Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By Route of Administration
- 9.3.3. South Africa Anesthesia Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By Route of Administration

10. South America Anesthesia Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Route of Administration
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Anesthesia Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By Route of Administration
- 10.3.2. Colombia Anesthesia Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By Route of Administration
- 10.3.3. Argentina Anesthesia Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Anesthesia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Merck & Co., Inc.
15.3. GSK Plc
15.4. Bayer AG
15.5. Dr. Reddy's Laboratories Ltd.
15.6. Viatris Inc.
15.7. AstraZeneca Plc
15.8. Abbott Laboratories Inc.
15.9. Sun Pharmaceutical Industries Ltd.
15.10. Eli Lilly and Company